The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
Open accessAbstract
AIMS/HYPOTHESIS: In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes. METHODS: trial (n = 7020), pooled data from four 24-week placebo-controlled trials (n = 2477) and a trial of empagliflozin vs glimepiride over 104 weeks (n = 1545). Analyses were performed using data from all participants and by tertiles of baseline aminotransferases. RESULTS: . AST changes showed similar patterns to ALT, but the reductions were considerably lower. CONCLUSIONS/INTERPRETATION: These highly consistent results suggest that empagliflozin reduces aminotransferases in individuals with type 2 diabetes, in a pattern (reductions in ALT>AST) that is potentially consistent with a reduction in liver fat, especially when ALT levels are high.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Leite, N. C., Salles, G. F., Araujo, A. L. E., Villela‐Nogueira, C. A., & Cardoso, C. R. L. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01718.x · Cited by 531
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Kotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Cornér, A., Bergholm, R., & Yki-Järvinen, H. (2008) · Diabetes Care · doi:10.2337/dc07-1463 · Cited by 196
Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168
Cited by
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Dufour, J.-F., Caussy, C., & Loomba, R. (2020) · Gut · doi:10.1136/gutjnl-2019-319104 · Cited by 193
Metadata
- Authors
- Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B.
- Venue
- Diabetologia
- Published
- 2018-07-31
- Volume
- 61
- Issue
- 10
- Pages
- 2155-2163
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2887583392
- Cited by
- 168
- References
- 7
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. https://app.cochat.ai/papers/10.1007/s00125-018-4702-3
- The paper
- Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018). Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia. https://doi.org/10.1007/s00125-018-4702-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.